

GMR  
EPIGENETICS

1635  
711 North Shoreline Blvd.  
Mountain View, CA 94043  
Phone: (650) 248-3617  
Fax: (650) 856-0598

To: Terra C. Gibbs  
Patent Examiner  
1911 South Clark Street  
Arlington, VA 22202-3503  
Tel: 703-306-3221

RECEIVED  
OCT 17 2003  
TECH CENTER 1600/2900

re: Sequence list of patent (Serial No: 09/643,128)

Oct. 10, 2003

Dear Terra C. Gibbs,

It was nice to talk to you over the phone. Enclosed please find a disk containing "Sequence List" and the print out of Sequence List in comply with the sequence rules, 37 C.F.R. 1.821-1.825. "The information recorded in computer readable form is identical to the written sequence listing".

However, we have corrected some sequence ID errors that were presented in original version, including: Seq ID aa =1, bb=2, cc=3, dd=4, zz=5, xx=6. Furthermore, sequences in the table with missing ID numbers are renumbered as Seq ID #7-56 in order.

Please feel free to contact me at 650-493-5000. ext. 63175, should you have questions or require additional information about this proposal.

Sincerely yours

Jifan Hu, M.D., Ph.D.  
Chief Scientific Officer  
GMR Epigenetics  
Phone: (650) 248-3617  
Fax: (650) 856-0598  
E-mail: [jifan@gmrusa.com](mailto:jifan@gmrusa.com) or [jifan@stanford.edu](mailto:jifan@stanford.edu)

RECEIVED  
NOV 12 2003  
TECH CENTER 1600/2900

## STATEMENT

To: United States Department of Commerce  
Patent and Trademark Office  
Washington, D.C. 20231

From: Jifan Hu, M.D., Ph.D.  
Andrew R. Hoffman, M.D.

re: Sequence list of patent (Serial No: 09/643,128)

Oct. 10, 2003

Dear Patent Examiner,


Enclosed are a computer disk and printout of "Sequence List" for the patent application, Serial No: 09/643,128. The sequences are entered in a format according to the sequence rules, 37 C.F.R. 1.821-1.825.

This is confirmed that "the information recorded in computer readable form is identical to the written sequence listing". However, we have corrected some sequence ID errors that were presented in original version, including: Seq ID aa =1, bb=2, cc=3, dd=4, zz=5, xx=6. Furthermore, sequences in the table with missing ID numbers are renumbered as Seq ID #7-56 in order.

Should you have questions for this petition, please do not hesitate to contact Dr. Jifan Hu at 650-248-3617 or e-mail at [jifan@gmrusa.com](mailto:jifan@gmrusa.com), or Dr. Andrew R. Hoffman at 650-725 2908, or e-mail at [arhoffman@Stanford.EDU](mailto:arhoffman@Stanford.EDU).

---

Sincerely yours



Jifan Hu, M.D., Ph.D.



Andrew R. Hoffman

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/643128	08-21-00	Hu et al.	GMR-001

EXAMINER	
Terra C. Gibbs	
ART UNIT	PAPER NUMBER
1635	15


Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures (see pages 3, 4, 11, 12, 13, 25, 26, and Table 1 of the specification) that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. §1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Terra C. Gibbs whose telephone number is (703) 306-3221. If the examiner cannot be reached, inquiries can be directed to the examiner's mentor, Sean McGarry, at (703) 305-5028, or Supervisory Patent Examiner, John LeGuyader, at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed to Patent Analyst, Katrina Turner, whose telephone number is (703) 305-3553.

  
KAREN A. LACOURCIERE, PH.D  
PRIMARY EXAMINER



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/643,128	08/21/2000	Jifan Hu	10583-005-999	8788

7590 10/01/2003

Dr. Jifan Hu  
president and Inventor  
GMR Epigenetics  
525 Del Rey Avenue, Suite b  
Sunnyvale, CA 94085

EXAMINER

GIBBS, TERRA C

ART UNIT	PAPER NUMBER
----------	--------------

1635

15

DATE MAILED: 10/01/2003

Please find below and/or attached an Office communication concerning this application or proceeding.